FIELD: medicine.
SUBSTANCE: pharmaceutical composition in a dose of 4 g a day containing at least 90 wt % of ethyl eicosapentaenoate is administered into an individual having initial fasting triglycerides within the approximate range of 500 mg/dl to 2000 mg/dl for a period of time effective to reduce fasting triglycerides by at least 15% as compared to initial fasting triglycerides before the first administration of the pharmaceutical composition. The second version involves administering approximately 4 g a day of the pharmaceutical composition containing at least 96 wt % ethyl eicosapentaenoate into an individual with initial fasting triglycerides from approximately 500 mg/dl to approximately 2000 mg/dl receiving neither any pharmaceutical composition, nor a concomitant statin therapy, for a period of time effective to reduce fasting triglycerides by at least 25% as compared to another similar individual. The third version provides reducing triglycerides and apoliprotein B in an individual having initial fasting triglycerides from approximately 500 mg/dl to approximately 2000 mg/dl and receiving no concomitant therapy changing the lipid profile, and involves administering approximately 4 g a day of the pharmaceutical composition containing at least 96 wt % of ethyl eicosapentaenoate for a 12-week period. The individual shows the fasting triglycerides reduction by at least 25% and the fasting apoliprotein B reduction as compared to the reference having initial triglycerides within the range from 500 mg/dl to approximately 2000 mg/dl and receiving neither any pharmaceutical composition, nor a concomitant therapy changing the lipid profile.
EFFECT: method improvement.
4 cl, 1 ex
